ALDH enzyme supplementation

PreclinicalSmall molecule

KKorea University Anam Hospital

ALDH enzyme supplementation is one of 35 small molecule programs targeting Advanced. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdvancedUnknown status

AdvancedPreclinical

Unknown status

Competition

Competitive Landscape

46 competitors in Advanced

#DrugCompanyPhaseTrials

Remodulin

United Therapeutics

Phase 3

1 2

Tecentriq

Roche

Phase 2

4 3

Qinlock

DDeciphera Pharmaceuticals, LLC

Phase 3

2 4

Lenvima

Eisai

Phase 2

3 5

Fludara

Sanofi

Phase 2

2 6

Yervoy

Bristol-Myers Squibb

Phase 2

2 7

Keytruda

Merck & Co.

Phase 2

2 8

Beyfortus

BeiGene

Phase 2

1 9

Nolvadex

AstraZeneca

Phase 2

1 10

Avastin

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced1 trial

ALDH Enzyme in CRF With Advanced GI Cancer

Unknown status·KKorea University Anam Hospital·N/A·NCT05030363·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALDH enzyme supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALDH enzyme supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALDH enzyme supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea University Anam Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorea University Anam Hospital

ALDH enzyme supplementation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced1 trial

References

Drug Info

Quick Facts

Related News